Natriuretic Peptides as the Basis of Peptide Drug Discovery for Cardiovascular Diseases

Abstract

: : Cardiovascular diseases (CVDs) are the leading global cause of death, accounting for more than 17.6 million deaths per year in 2016, a number that is expected to grow to more than 23.6 million by 2030. While many technologies are currently under investigation to improve the therapeutic outcome of CVD complications, only few medications have been approved. Therefore, new approaches to treat CVD are urgently required. Peptides regulate numerous physiological processes, mainly by binding to specific receptors and inducing a series of signals, neurotransmissions or the release of growth factors. Importantly, peptides have also been shown to play an important role in the circulatory system both in physiological and pathological conditions. Peptides, such as angiotensin II, endothelin, urotensin-II, urocortins, adrenomedullin and natriuretic peptides have been implicated in the control of vascular tone and blood pressure as well as in CVDs such as congestive heart failure, atherosclerosis, coronary artery disease, and pulmonary and systemic hypertension. Hence it is not surprising that peptides are becoming important therapeutic leads in CVDs. This article will review the current knowledge about peptides and their role in the circulatory system, focusing on the physiological roles of natriuretic peptides in the cardiovascular system and their implications in CVDs.

Beyond the Low Hanging Fruit: Rationally Designed Peptide as Regulators of Protein-Protein Interactions and Their Applications to Human Disease

“…In addition, they are highly bioactive, very specific, demonstrate low toxicity, and in many cases are developed from natural endogenous scaffolds with known biological activity, thereby making them particularly attractive therapeutic agents [27][28][29]. Over the years, peptides and peptidomimetics have been evolved as promising therapeutic agents in the treatment of different diseases [21,28,30,31] such as parasitic diseases [32][33][34], cancer [35,36], diabetes [37], and cardiovascular diseases [8,10,[38][39][40][41][42]. There is an increased interest in regulation of PPIs to target intracellular signaling events.…”

Proceedings of the 36th European and the 12th International Peptide Symposium

“…In addition, they are highly bioactive, very specific, demonstrate low toxicity, and in many cases are developed from natural endogenous scaffolds with known biological activity, thereby making them particularly attractive therapeutic agents [27][28][29]. Over the years, peptides and peptidomimetics have been evolved as promising therapeutic agents in the treatment of different diseases [21,28,30,31] such as parasitic diseases [32][33][34], cancer [35,36], diabetes [37], and cardiovascular diseases [8,10,[38][39][40][41][42]. There is an increased interest in regulation of PPIs to target intracellular signaling events.…”

“…-Glu36 -Val37 -Gly38 -Trp39 -Tyr40 -Arg41 -Pro42 -Pro 43 -Phe 44 -Ser 45 -Arg 46 -Val 47 -Val 48 -His 49 -Leu 50 -Tyr 51 -Arg 52 -Asn 53 -Gly 54 -Lys 55 -OH. Affinity purified polyclonal antibodies against peptide MOG36-55 (sequence 36-55 of [KG]5MOG35-55) were produced in rabbits via immunization process by Davids Biotechnologies GMBH (Germany), while the epitope recognized by the antibodies is located into sequence 38-49.The developed ELISA includes the following procedure:Several modifications of peptide sequence may occur during the peptide synthesis and storage.…”

Beyond the Low Hanging Fruit: Rationally Designed Peptide as Regulators of Protein-Protein Interactions and Their Applications to Human Disease

“…In addition, they are highly bioactive, very specific, demonstrate low toxicity, and in many cases are developed from natural endogenous scaffolds with known biological activity, thereby making them particularly attractive therapeutic agents [27][28][29]. Over the years, peptides and peptidomimetics have been evolved as promising therapeutic agents in the treatment of different diseases [21,28,30,31] such as parasitic diseases [32][33][34], cancer [35,36], diabetes [37], and cardiovascular diseases [8,10,[38][39][40][41][42]. There is an increased interest in regulation of PPIs to target intracellular signaling events.…”